Log in to search using one of your social media accounts:

 

New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 21, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 21, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 20, 2018 Category: Pharmaceuticals Source Type: news

New tremfya ® (guselkumab) data demonstrates long-term skin clearance in patients with moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

Johnson & johnson consumer presents new scientific research at 2018 american academy of dermatology annual meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

Plastic And Reconstructive Surgery Journal Publishes Ten-Year Clinical Study Data Highlighting Safety Of MENTOR ® MemoryShape® Gel Breast Implants
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 16, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 15, 2018 Category: Pharmaceuticals Source Type: news

ERLEADA ™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 9, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2018 CAGNY Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen enters into worldwide collaboration with theravance biopharma for oral, pan-jak inhibitor drug candidate for the treatment of inflammatory bowel disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 7, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 1, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA ® (abiraterone acetate) and Erdafitinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 25, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2017 Fourth-Quarter Results:
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 23, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Issues Statement on ZYTIGA ® Inter Partes Reviews
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 18, 2018 Category: Pharmaceuticals Source Type: news

FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO ® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 16, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients ’ Lives
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 5, 2018 Category: Pharmaceuticals Source Type: news

Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 3, 2018 Category: Pharmaceuticals Source Type: news

LANDMARK SCHIZOPHRENIA DATA THAT BRINGS HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVES FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA ® (paliperidone palmitate) LABEL
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 3, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2018
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 2, 2018 Category: Pharmaceuticals Source Type: news

Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 22, 2017 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 21, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in 36th Annual JP Morgan Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 19, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 19, 2017 Category: Pharmaceuticals Source Type: news

Janssen and Leading Advocacy Organizations Introduce Cancer.com, a Customizable Online Destination for People Impacted by Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 13, 2017 Category: Pharmaceuticals Source Type: news

DARZALEX ® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 12, 2017 Category: Pharmaceuticals Source Type: news

New Data for DARZALEX ® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 12, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO ® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 11, 2017 Category: Pharmaceuticals Source Type: news

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 ½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 10, 2017 Category: Pharmaceuticals Source Type: news

Phase 3 Study Evaluating IMBRUVICA ® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 5, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the BMO Capital Markets Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 1, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 30, 2017 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA ® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
Provides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1 (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 22, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX ® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 21, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 21, 2017 Category: Pharmaceuticals Source Type: news

New Real-World Analysis Shows INVOKANA ® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 17, 2017 Category: Pharmaceuticals Source Type: news

OneTouch ® Launches #SmallVictories to Honor People Living with Diabetes with Unexpected Celebrations during Diabetes Awareness Month
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 17, 2017 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 14, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 13, 2017 Category: Pharmaceuticals Source Type: news

New phase 2 data show treatment with tremfya ® (guselkumab) improved psoriatic arthritis symptoms through one year
Longer-Term Results Demonstrate Continued Efficacy of Anti-Interleukin 23 Monoclonal Antibody TREMFYA ® in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 7, 2017 Category: Pharmaceuticals Source Type: news

Stelara ® (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 6, 2017 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 3, 2017 Category: Pharmaceuticals Source Type: news

Newly Created Johnson & Johnson Institute Will Address Global Needs in Healthcare Professional Education
Johnson& Johnson Institute offers professional education to help clinical and administrative healthcare professionals adapt to a rapidly changing healthcare environment (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 2, 2017 Category: Pharmaceuticals Source Type: news

ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX ® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 1, 2017 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Health Partner Leverages the Science of Behavior Change with Technology to Help Patients Better Prepare for Surgery and Recovery
Digital platform enables patients to physically, mentally and emotionally navigate certain surgeries (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 1, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves New 10 mg Dosing for XARELTO ® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2017 Category: Pharmaceuticals Source Type: news

New VA and Johnson & Johnson Campaign Encourages Public to Take Note of Veterans at Risk for Suicide
Public Service Announcement Narrated by Tom Hanks Encourages People to ‘Be There’ for Veterans and Service Members (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2017 Category: Pharmaceuticals Source Type: news

New DePuy Synthes Spine Technologies Help Simplify Minimally Invasive Surgery by Enhancing Efficiency and Reducing Steps
One-Tool VIPER PRIME ™ Pedicle Screw System and CONCORDE® Clear MIS Discectomy Tool for MIS Spinal Fusion Surgery Launch in the United States (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 28, 2017 Category: Pharmaceuticals Source Type: news